Capecitabine (breast indication entry)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CAPECITABINE-BREAST |
|---|---|
| Type | Drug |
| Aliases | XelodaКапецитабін (ентрі для РМЗ) |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | Oral fluoropyrimidine prodrug |
|---|---|
| Mechanism | Note: aliasing entry. Prefers GI-agent's DRUG-CAPECITABINE if already created. This file kept as a placeholder for breast-specific dosing context if needed; in practice the engine uses DRUG-CAPECITABINE. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Use DRUG-CAPECITABINE (created by GI agent for colorectal); this entry exists only to make the breast-builder script self-contained. Recommend deletion + reuse of cross-disease entry once both branches merge.
Used By
Regimens
REG-TUCATINIB-TRASTUZUMAB-CAPECITABINE-BREAST- Tucatinib + trastuzumab + capecitabine (HER2+ metastatic ≥3L, especially with brain metas...